Initial Quality of Life and Toxicity Analysis of a Randomized Phase 3 Study of Moderately Hypofractionated Radiation Therapy With or Without Androgen Suppression for Intermediate-Risk Adenocarcinoma of the Prostate: PCG GU003

Initial Quality of Life and Toxicity Analysis of a Randomized Phase 3 Study of Moderately Hypofractionated Radiation Therapy With or Without Androgen Suppression for Intermediate-Risk Adenocarcinoma of the Prostate: PCG GU003

Purpose: Our objective was to report the quality of life (QoL) analysis and toxicity in patients with intermediate-risk prostate cancer treated with or without androgen deprivation therapy (ADT) in Proton Collaborative Group (PCG) GU003. Methods and Materials: Between 2012 and 2019, patients with in...

Full description

Bibliographic Details
Main Authors: Brady S. Laughlin, MD, Cameron S. Thorpe, MD, Todd A. DeWees, PhD, Molly M. Voss, BA, John H. Chang, MD, William F. Hartsell, MD, Christopher C. Sinesi, MD, Jean-Claude M. Rwigema, MD, Sameer R. Keole, MD, Vinai Gondi, MD, Carlos E. Vargas, MD
Format: Article
Language:English
Published: Elsevier 2023-05-01
Series:Advances in Radiation Oncology
Online Access:http://www.sciencedirect.com/science/article/pii/S2452109422002482

Internet

http://www.sciencedirect.com/science/article/pii/S2452109422002482

Similar Items